Cited by 359Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsClinical Laboratory Practices and Quality Control

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Vanderstichele, Hugo, Bibl, Mirko, Engelborghs, Sebastiaan, Le Bastard, Nathalie, Lewczuk, Piotr, Molinuevo, Jose Luis, Parnetti, Lucilla, Perret‐Liaudet, Armand, Shaw, Leslie M., Teunissen, Charlotte, Wouters, Dirk, Blennow, Kaj·2012·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2011.07.004

Open this paper in CoChat — free account

Abstract

Background: Numerous studies show that the cerebrospinal fluid biomarkers total tau (T‐tau), tau phosphorylated at threonine 181 (P‐tau 181P), and amyloid‐β (1‐42) (Aβ 1–42) have high diagnostic accuracy for Alzheimer's disease. Variability in concentrations for Aβ 1–42, T‐tau, and P‐tau 181P drives the need for standardization. Methods: Key issues were identified and discussed before the first meeting of the members of the Alzheimer's Biomarkers Standardization Initiative (ABSI). Subsequent ABSI consensus meetings focused on preanalytical issues. Results: Consensus was reached on preanalytical issues such as the effects of fasting, different tube types, centrifugation, time and temperature before storage, storage temperature, repeated freeze/thaw cycles, and length of storage on concentrations of Aβ 1–42, T‐tau, and P‐tau 181P in cerebrospinal fluid. Conclusions: The consensus reached on preanalytical issues and the recommendations put forward during the ABSI consensus meetings are presented in this paper.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2011.07.004

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336
Defining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citation
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citation
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
Doody, R. S., Stevens, J. E., Beck, C., Dubinsky, R., Kaye, J. A., Gwyther, L. P., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,708

Flagged first, then by citations

Show all 63 references

Research works printed but not linked: 3

Morris JC, 1999, Alzheimer's Disease, 11
10.1016/j.jalz.2011.03.008 · DOI · Paper page
DSlats.Hour‐to‐hour variability CSF biomarkers in AD patients. Presented at the Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD) July 10–15 2010 Honolulu Hawaii.

Sorted by citations

Items 201–300 of 359

Diffusion MRI tractography of the locus coeruleus‐transentorhinal cortex connections using GO‐ESP
Solders, S. K., Galinsky, V. L., Clark, A. L., Sorg, S. F., Weigand, A. J., Bondi, M. W., & Frank, L. R. (2021) · Magnetic Resonance in Medicine · doi:10.1002/mrm.29088 · Cited by 12
Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer’s Disease, Mild Cognitive Impairment, or Healthy Control Individuals
Berge, G., Lauridsen, C., Sando, S. B., Holder, D., Møller, I., Aasly, J. O., Bråthen, G., Savage, M. J., & White, L. R. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150234 · Cited by 14
Comparison of two commercial enzyme-linked immunosorbent assays for cerebrospinal fluid measurement of amyloid β1–42 and total tau
Leko, M. B., Vogrinc, Ž., Diana, A., Klepac, N., Borovečki, F., Hof, P. R., & Šimić, G. (2013) · Translational Neuroscience · doi:10.2478/s13380-013-0123-4 · Cited by 15
Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer’s Disease
Li, Y., Huang, X., Fowler, C. J., Lim, Y. Y., Laws, S. M., Faux, N. G., Doecke, J. D., Trounson, B. O., Pertile, K. K., Rumble, R. L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147867 · Cited by 14
Cerebrospinal fluid p‐tau181, 217, and 231 in definite Creutzfeldt–Jakob disease with and without concomitant pathologies
Emeršič, A., Ashton, N. J., Vrillon, A., Lantero‐Rodriguez, J., Mlakar, J., Kramberger, M. G., González‐Ortiz, F., Kac, P. R., Dulewicz, M., Hanrieder, J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13907 · Cited by 12
Self-citation
Strategies to assess and optimize stability of endogenous amines during cerebrospinal fluid sampling
Noga, M. J., Zielman, R., van Dongen, R. M., Bos, S., Harms, A. C., Terwindt, G. M., van den Maagdenberg, A. M. J. M., Hankemeier, T., & Ferrari, M. D. (2018) · Metabolomics · doi:10.1007/s11306-018-1333-0 · Cited by 13
Collection and Analyses of Cerebrospinal Fluid for Pediatric Translational Research
Cameron, S., Gillio‐Meina, C., Ranger, A. M., Choong, K. L. M., & Fraser, D. D. (2019) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2019.05.011 · Cited by 14
Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
Bellomo, G., Cataldi, S., Paciotti, S., Paoletti, F. P., Chiasserini, D., & Parnetti, L. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00689-0 · Cited by 15
Self-citation
Spatial navigation deficits in early Alzheimer’s disease: the role of biomarkers and APOE genotype
Laczó, M., Svacova, Z., Lerch, O., Martinkovič, L., Krejčí, M., Nedelská, Z., Horáková, H., Maťoška, V., Vyhnálek, M., Hort, J., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13151-8 · Cited by 13
Physical Exercise May Increase Plasma Concentration of High-Density Lipoprotein-Cholesterol in Patients With Alzheimer’s Disease
Jensen, C. S., Musaeus, C. S., Frikke‐Schmidt, R., Andersen, B. B., Beyer, N., Gottrup, H., Høgh, P., Vestergaard, K., Wermuth, L., Frederiksen, K. S., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00532 · Cited by 11
Biomarkers of dementia: Comparison of electrochemiluminescence results and reference ranges with conventional ELISA
Regeniter, A., Kühle, J., Baumann, T., Sollberger, M. A., Herdener, M., Kunze, U., Camuso, M. C., & Monsch, A. U. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.019 · Cited by 12
Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer’s Disease Patients and Controls after Correction for Ventricular Volumes
van Waalwijk van Doorn, L. J. C., Gispert, J. D., Kuiperij, H. B., Claassen, J. A. H. R., Arighi, A., Baldeiras, I., Blennow, K., Bozzali, M., Castelo-Branco, M., Cavedo, E., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160668 · Cited by 13
Self-citation
Failure to stop autocorrect errors in reading aloud increases in aging especially with a positive biomarker for Alzheimer’s disease.
Gollan, T. H., Smirnov, D. S., Salmon, D. P., & Galasko, D. (2020) · Psychology and Aging · doi:10.1037/pag0000550 · Cited by 13
Comparison of two methods for the analysis of CSF Aβ and tau in the diagnosis of Alzheimer's disease.
Faull, M., Ching, S., Jarmolowicz, A. I., Beilby, J. P., & Panegyres, P. K. (2014) · Europe PMC (PubMed Central) · Cited by 12
Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe
Miller, A.-M., Balasa, M., Blennow, K., Gardiner, M., Rutkowska, A., Scheltens, P., Teunissen, C. E., Visser, P. J., Winblad, B. G., Waldemar, G., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170502 · Cited by 12
Self-citation
Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study
Dhiman, K., Villemagne, V. L., Fowler, C. J., Bourgeat, P., Li, Q., Collins, S. J., Bush, A. I., Rowe, C. C., Masters, C. L., Ames, D. J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10051045 · Cited by 11
Self-citation
Spatial navigation questionnaires as a supportive diagnostic tool in early Alzheimer’s disease
Laczó, M., Svatkova, R., Lerch, O., Martinkovič, L., Zuntychová, T., Nedelská, Z., Horáková, H., Vyhnálek, M., Hort, J., & Laczó, J. (2024) · iScience · doi:10.1016/j.isci.2024.109832 · Cited by 11
Toward alpha‐synuclein seed amplification assay in clinical practice
Verdurand, M., Kaczorowski, F., Dautricourt, S., Desestret, V., Formaglio, M., Mollion, H., Petitnicolas, G., Afifi, A., Fourier, A., Garnier‐Crussard, A., et al. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70066 · Cited by 11
Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis
Michaud, T. L., Initiative, A. D. N., Kane, R. L., McCarten, J. R., Gaugler, J. E., Nyman, J. A., & Kuntz, K. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150066 · Cited by 10
Associations Between Plasma Klotho with Renal Function and Cerebrospinal Fluid Amyloid-β Levels in Alzheimer’s Disease: The Chongqing Ageing & Dementia Study
Ren, J.-R., Wang, Z., Cheng, Y., He, C.-Y., Jian, J.-M., Fan, D., Shen, Y., Chen, D., Li, H., Yi, X., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221107 · Cited by 10
Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer’s disease in individuals with mild cognitive impairment: The NORFACE cohort
Marquié, M., García‐Sánchez, A., Alarcón‐Martín, E., Martínez, J., Castilla-Martí, M., Castilla‐Martí, L., Orellana, A., Montrreal, L., de Rojas, I., García‐González, P., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1076177 · Cited by 10
Positron Emission Tomography/Computed Tomography Imaging in Therapeutic Clinical Trials in Alzheimer’s Disease: An Overview of the Current State of the Art of Research
Triumbari, E. K. A., Chiaravalloti, A., Schillaci, O., Mercuri, N. B., & Liguori, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240349 · Cited by 9
Detection of Alzheimer's Disease Using Graph-Regularized Convolutional Neural Network Based on Structural Similarity Learning of Brain Magnetic Resonance Images
Yang, K., Mohammed, E. A., & Far, B. H. (2021) · IEEE International Conference on Information Reuse and Integration (IRI) · doi:10.1109/iri51335.2021.00051 · Cited by 10
Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals
Dhiman, K., Villemagne, V. L., Fowler, C. J., Bourgeat, P., Li, Q., Collins, S. J., Rowe, C. C., Masters, C. L., Ames, D. J., Blennow, K., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12377 · Cited by 8
Self-citation
Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease
Magalhaes, C. A., Figueiró, M., Fraga, V. G., Mateo, E. C. C., Toledo, A. A. S. F., Ferriani, M. D. G. C., Caramelli, P., & Gomes, K. B. (2015) · Jornal Brasileiro de Patologia e Medicina Laboratorial · doi:10.5935/1676-2444.20150059 · Cited by 10
Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects
Somers, C., Lewczuk, P., Sieben, A., Broeckhoven, C. V., Deyn, P. P. D., Kornhuber, J., Martin, J., Bjerke, M., & Engelborghs, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180563 · Cited by 10
Self-citation
CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment
Brisson, M., Brodeur, C., Guillon, L. L., Masellis, M., Stoessl, A. J., Tamm, A., Zukotynski, K., Ismail, Z., Gauthier, S. G., Rosa‐Neto, P., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12098 · Cited by 9
Una nueva aproximación en el diagnóstico de la enfermedad de Alzheimer con biomarcadores: descripción del AD-CSF-Index
Molinuevo, J. L., Gispert, J. D., Pujol, J., Rojas, S., Plarrumaní, A. L., Balasa, M., Antonell, A., Sánchez‐Valle, R., & González, L. R. (2012) · Revista de Neurología · doi:10.33588/rn.5409.2012157 · Cited by 9
Self-citation
Effect of Patient-Specific Preanalytic Variables on CSF Aβ1–42 Concentrations Measured on an Automated Chemiluminescent Platform
Darrow, J. A., Calabro, A., Gannon, S., Orusakwe, A., Esquivel, R. N., Traynham, C. J., Rao, A. S., Gulyani, S., Khingelova, K., Bandeen‐Roche, K., et al. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa145 · Cited by 9
Cerebrospinal fluid, brain, and spinal cord levels of L‐aspartate signal excitatory neurotransmission abnormalities in multiple sclerosis patients and experimental autoimmune encephalomyelitis mouse model
Errico, F., Gilio, L., Mancini, A., Nuzzo, T., Bassi, M. S., Bellingacci, L., Buttari, F., Dolcetti, E., Bruno, A., Galifi, G., et al. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15884 · Cited by 9
The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer’s Disease: Shortcomings in Prodromal Diagnosis
Szalárdy, L., Zádori, D., Klivènyi, P., & Vécsei, L. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160037 · Cited by 10
Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
Tsantzali, I., Foska, A., Sideri, E., Routsi, E., Tsomaka, E., Kitsos, D. K., Zompola, C., Bonakis, A., Giannopoulos, S., Voumvourakis, K. I., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10081879 · Cited by 9
How far is the goal of applying β-amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer’s disease with standardization of measurements?
Zou, Y., Yu, S., Ma, X., Ma, C., Mao, C., Mu, D., Li, L., Gao, J., & Qiu, L. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.11.013 · Cited by 9
Concordancia entre la PET cerebral con 18 F-FDG y los biomarcadores en líquido cefalorraquídeo en el diagnóstico de enfermedad de Alzheimer
Rubí, S., Noguera, A., Tarongí, S., Oporto, M., García, A., Vico, H., Espino, A., Picado, M. J., Mas, A., Peña, C., et al. (2017) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2017.05.003 · Cited by 9
Leveraging global resources to end the Alzheimer's pandemic
Carrillo, M. C. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1768 · Cited by 9
Standardized Procedures for Blood and Cerebrospinal Fluid Collection and Storage in Neurodegenerative Biomarker Research: A Comprehensive Review
Kwon, H. S., Kim, G. H., Park, S. A., Moon, S. Y., Jang, J., Park, K. H., Park, Y. H., Lim, J., Yang, D. W., Choi, S. H., et al. (2025) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2025.24.3.162 · Cited by 9
Concordance between amyloid PET and CSF biomarkers in clinical setting: a cross-platform comparison and in-depth analysis of discordant cases
Cerman, J., Škorvagová, A., Vyhnálek, M., Veverová, K., Dvořák, K., Kozák, Š., Kavka, A., & Hort, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-23759-5 · Cited by 9
Automation on an Open-Access Platform of Alzheimer’s Disease Biomarker Immunoassays
Gille, B., Dedeene, L., Stoops, E., Demeyer, L., François, C., Lefever, S., Schaepdryver, M. D., Brix, B., Vandenberghe, R. R., Tournoy, J., et al. (2018) · SLAS TECHNOLOGY · doi:10.1177/2472630317750378 · Cited by 8
Self-citation
ABI3 Is a Novel Early Biomarker of Alzheimer’s Disease
Cao, M., Liu, J., Zhang, X., Yang, T., Wang, Y., Hou, Y., Qiao, S., Cui, Y., Wang, Y., & Wang, P. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215635 · Cited by 8
Biomarkers for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00007-0 · Cited by 9
Bias-generating factors in biofluid amyloid-β measurements for Alzheimer’s disease diagnosis
Park, S., & Kim, Y. S. (2021) · Biomedical Engineering Letters · doi:10.1007/s13534-021-00201-z · Cited by 8
Neue diagnostische Methoden bei Demenzen
Wiltfang, J. (2015) · Der Nervenarzt · doi:10.1007/s00115-014-4177-5 · Cited by 5
β-Amyloid in Cerebrospinal Fluid: How to Keep It Floating (Not Sticking) by Standardization of Preanalytic Processes and Collection Tubes
Strand, H., Garabet, L., Bjelke, B., Sithiravel, C., Hardang, I. M., & Moe, M. K. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab024 · Cited by 7
Habitual tea consumption and postoperative delirium after total hip/knee arthroplasty in elderly patients: The PNDABLE study
Xu, L., Li, X., Dong, R., Wang, B., & Bi, Y. (2022) · Brain and Behavior · doi:10.1002/brb3.2612 · Cited by 7
Estudio CORCOBIA: determinación de puntos de corte de biomarcadores de enfermedad de Alzheimer en LCR en una cohorte clínica
Puig‐Pijoan, A., García‐Escobar, G., Fernández‐Lebrero, A., Borràs, R. M. M., Sánchez‐Benavides, G., Navalpotro‐Gómez, I., Cascales‐Lahoz, D., Suárez‐Calvet, M., Grau‐Rivera, O., Boltes, A., et al. (2022) · Neurología · doi:10.1016/j.nrl.2022.05.005 · Cited by 6
Autocorrection if→of function words in reading aloud: A novel marker of Alzheimer’s risk.
Gollan, T. H., Stasenko, A., Li, C., Smirnov, D. S., Galasko, D. R., & Salmon, D. P. (2022) · Neuropsychology · doi:10.1037/neu0000829 · Cited by 7
The Australian Traumatic Brain Injury Initiative: Statement of Working Principles and Rapid Review of Methods to Define Data Dictionaries for Neurological Conditions
Bagg, M. K., Hicks, A. J., Hellewell, S. C., Ponsford, J. L., Lannin, N. A., O'Brien, T. J., Cameron, P. A., Cooper, D. J., Rushworth, N., Gabbe, B. J., et al. (2024) · Neurotrauma Reports · doi:10.1089/neur.2023.0116 · Cited by 6
Concordance between brain 18 F-FDG PET and cerebrospinal fluid biomarkers in diagnosing Alzheimer's disease
Rubí, S., Noguera, A., Tarongí, S., Oporto, M., García, A., Vico, H., Espino, A., Picado, M. J., Mas, A., Peña, C., et al. (2018) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2017.10.017 · Cited by 6
Relationship Between General Cognition, Visual Assessed Cortical Atrophy, and Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease: A Cross-Sectional Study from a Chinese PUMCH Cohort
Mao, C., Sha, L., Li, J., Huang, X., Chu, S., Lei, D., Wang, J., Dong, L., Liu, C., Xu, Q., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210344 · Cited by 6
Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients
Chirila, F. V., Xu, G., Fontaine, D., Kern, G., Khan, T. K., Brandt, J., Konishi, Y., Nebe‐von‐Caron, G., White, C. L., & Alkon, D. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-21796-y · Cited by 6
Importance of Pre-analytical Stability for CSF Biomarker Testing
Willemse, E. A. J., & Teunissen, C. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-01225-4_5 · Cited by 6
Self-citation
Validating blood tests as a possible routine diagnostic assay of Alzheimer’s disease
Kodosaki, E., Zetterberg, H., & Heslegrave, A. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2289553 · Cited by 27
Sodium signal intensity of CSF using 1H‐guided 23Na‐MRI as a potential noninvasive biomarker in Alzheimer's disease
Kerl, H. U., Baazaoui, H., Herrmann, K., Adlung, A., Ludwig, N. K., Hausner, L., Frölich, L., Schad, L. R., Groden, C., & Mohamed, S. A. (2024) · Journal of Neuroimaging · doi:10.1111/jon.13216 · Cited by 5
Evaluation of the EUROIMMUN automated chemiluminescence immunoassays for measurement of four core biomarkers for Alzheimer’s disease in cerebrospinal fluid
Römpler, K., Arendt, P., Brix, B., Borchardt-Lohölter, V., Schulz, A., Busse, M., & Busse, S. (2024) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2024.e00425 · Cited by 5
Harnessing topological machine learning in Raman spectroscopy: Perspectives for Alzheimer’s disease detection via cerebrospinal fluid analysis
Conti, F., Banchelli, M., Bessi, V., Cecchi, C., Chiti, F., Colantonio, S., D’Andrea, C., de Angelis, M., Moroni, D., Nacmias, B., et al. (2024) · Journal of the Franklin Institute · doi:10.1016/j.jfranklin.2024.107249 · Cited by 5
Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach
Vanderstichele, H., & Kodadek, T. J. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt253 · Cited by 5
Self-citation
Parkinsonian gait in aging: A feature of Alzheimer's pathology?
Morel, E., Armand, S., Assal, F., & Allali, G. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.110905 · Cited by 5
Clinical characteristics of patients with suspected Alzheimer’s disease within a CSF Aß-ratio grey zone
Yosypyshyn, D., Kučikienė, D., Ramakers, I. H. G. B., Schulz, J. B., Initiative, A. D. N., Reetz, K., & Costa, A. S. (2023) · Neurological Research and Practice · doi:10.1186/s42466-023-00262-8 · Cited by 5
The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers?
Fenouil, T., Fourier, A., Quadrio, I., Streichenberger, N., Bernardini, S., Zima, T., Perret‐Liaudet, A., & Meyronet, D. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.06.004 · Cited by 5
Self-citation
Neurochemical Dementia Diagnostics for Alzheimer‘s Disease and Other Dementias: An ISO 15189 Perspective
Waedt, J., Kleinow, M., Kornhuber, J., & Lewczuk, P. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.63 · Cited by 5
Self-citation
Pathogenesis of Alzheimer’s disease: Involvement of the Choroid PlexusPreprint
Čarná, M. E., Onyango, I. G., Katina, S., Holub, D., Nezvedová, M., Jha, D., Nedelská, Z., Lacovich, V., Vyvere, T. V., Houbrechts, R., et al. (2021) · medRxiv · doi:10.1101/2021.07.29.21260696 · Cited by 5
Plasma lipid dysregulation reflecting cerebrospinal fluid profile predicts Alzheimer’s disease progression
Novau-Ferré, N., Panisello, L., García‐González, P., Mateu-Fabregat, J., Cantero, J. L., Atienza, M., Boada, M., Ruiz, A., & Bulló, M. (2025) · Age and Ageing · doi:10.1093/ageing/afaf363 · Cited by 4
Parkinsonism is a Phenotypical Signature of Amyloidopathy in Patients with Gait Disorders
Allali, G., Kern, I., Laidet, M., Armand, S., & Assal, F. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171055 · Cited by 4
Alzheimer Disease Detection from Raman Spectroscopy of the Cerebrospinal Fluid via Topological Machine Learning
Conti, F., Banchelli, M., Bessi, V., Cecchi, C., Chiti, F., Colantonio, S., D’Andrea, C., de Angelis, M., Moroni, D., Nacmias, B., et al. (2023) · doi:10.3390/engproc2023051014 · Cited by 4
Functional discrimination of CSF from Alzheimer’s patients in a brain on chip platform
Miny, L., Rontard, J., Allouche, A., Violle, N., Dubuisson, L., Batut, A., Ponomarenko, A., Talbi, R., Gautier, H. O. B., Maisonneuve, B. G. C., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-97186-x · Cited by 4
Molecular profiling in Parkinsonian syndromes: CSF biomarkers
Paoletti, F. P., Gaetani, L., & Parnetti, L. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.002 · Cited by 5
Self-citation
Alzheimer’s Disease Cerebrospinal Fluid (CSF) Biomarkers
Khan, T. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804832-0.00005-5 · Cited by 5
Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
Ma, Y., Norton, D., Hulle, C. A. V., Chappell, R. J., Lazar, K. K., Jonaitis, E. M., Koscik, R. L., Clark, L. R., Krause, R. A., Andréasson, U., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12194 · Cited by 3
Self-citation
Elecsys CSF AD immunoassays: Sample stability for a new pre‐analytical protocol for fresh CSF
Manuilova, E., Schrurs, I., Rutz, S., McIlwrick, S., Goldhardt, O., Sommer, P., & Grimmer, T. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70797 · Cited by 3
The effect of preanalytical factors on cerebrospinal fluid and plasma proteomics: a systematic experimental study
Tatsumi, M., Miyakawa, T., Enokida, T., Kaneko, H., Saito, K., Hidese, S., Takahashi, Y., Goto, Y., Kunugi, H., & Hattori, K. (2026) · Clinical Proteomics · doi:10.1186/s12014-026-09604-5 · Cited by 3
Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO
Puerta, R., de Rojas, I., García‐González, P., Olivé, C., Sotolongo‐Grau, Ó., García‐Sánchez, A., García‐Gutiérrez, F., Montrreal, L., Tartari, J. P., Sanabria, Á., et al. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01581-6 · Cited by 4
Pre-Analytical and Analytical Critical Factors Influencing the High Variability of the Concentrations Levels of Alzheimer Disease Biomarkers in Cerebral Spinal Fluid
Perret‐Liaudet, A., Dorey, A., Tholance, Y., Dumont, B., & Quadrio, I. (2013) · InTech eBooks · doi:10.5772/55512 · Cited by 3
Self-citation
Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment
Lewczuk, P. (2014) · Advances in Geriatrics · doi:10.1155/2014/891780 · Cited by 3
Self-citation
Lumbar puncture increases Alzheimer’s disease biomarker levels in cerebrospinal fluid of rhesus monkeys
Xu, J., Li, H., Hu, Y., Wu, S., Wu, L., Lei, X., Lv, L., Lu, Y., Wu, J., Li, J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109436 · Cited by 3
Genetic variability of incretin receptors affects the occurrence of neurodegenerative diseases and their characteristics
Vogrinc, D., Redenšek, S., Blagus, T., Trošt, M., Kramberger, M. G., Emeršič, A., Čučnik, S., Goričar, K., & Dolžan, V. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39157 · Cited by 3
Are There Shortages and Regional Disparities in Lecanemab Treatment Facilities? A Cross-Sectional Study
Ohashi, K., Takahashi‐Iwata, I., Zhao, J., Sakushima, K., Yabe, I., & Ogasawara, K. (2024) · Health Services Insights · doi:10.1177/11786329241299312 · Cited by 3
The Soluble Platelet‐Derived Growth Factor β Receptor Induces Postoperative Delirium by Downregulating the Clearance of β‐Amyloid in the Brain
Guo, Z., Zhang, C., Wang, X., Chen, W., & Guo, Z. (2025) · Brain and Behavior · doi:10.1002/brb3.70436 · Cited by 3
Klinisch-validierte molekulare Biomarker neurodegenerativer Demenzerkrankungen
Wiltfang, J. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4086-7 · Cited by 3
Novel CSF Biomarkers for Alzheimer's Disease
Burchell, J. T., & Panegyres, P. K. (2015) · Future Neurology · doi:10.2217/fnl.15.41 · Cited by 3
Guidelines on Cerebrospinal Fluid Analysis
Hegen, H., Teunissen, C. E., Sellebjerg, F. T., Tumani, H., & Deisenhammer, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-01225-4_24 · Cited by 3
Self-citation
Serum proteomics reveals APOE dependent and independent protein signatures in Alzheimer’s disease
Frick, E. A., Emilsson, V., Jonmundsson, T., Steindorsdottir, A. E., Johnson, E. C. B., Puerta, R., Dammer, E. B., Shantaraman, A., Cano, A., Boada, M., et al. (2023) · doi:10.1101/2023.11.08.23298251 · Cited by 3
Where Should I Draw the Line: PET-Driven, Data-Driven, or Manufacturer Cut-Off?
Sánchez‐Soblechero, A., López‐García, S., Lage, C., Fernández‐Matarrubia, M., Irure, J., López‐Hoyos, M., Jiménez-Bonilla, J. F., Quirce, R., de Arcocha-Torres, M., Cuenca-Vera, O., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230678 · Cited by 2
Sleep quality and cerebrospinal fluid oxysterols in degenerative dementias: correlations and possible biomedical implications
Pradotto, L., Cattaldo, S., Priano, L., Cremascoli, R., Prina, E., Milesi, A., Mai, S., Piterà, P., Tripodi, D., Poli, G., et al. (2024) · Redox Experimental Medicine · doi:10.1530/rem-24-0013 · Cited by 2
Storage-dependent variability in Alzheimer disease-related plasma biomarker results using the Fujirebio Lumipulse G1200 platform
Choucair, I., Lee, T., Eldik, L. J. V., Dage, J. L., Gold, B. T., Abner, E. L., Jicha, G. A., & Nelson, P. T. (2025) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaf115 · Cited by 2
Cerebrospinal fluid sclerostin levels in the early Alzheimer's disease stages
Dicarlo, M., Pignataro, P., Urso, D., Zecca, C., Dell’Abate, M. T., Borlizzi, F., Gnoni, V., Giugno, A., Oranger, A., Colaianni, G., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70297 · Cited by 2
Liquorbiomarker zur Frühdiagnostik der Alzheimerdemenz
Wiltfang, J. (2015) · Therapeutische Umschau · doi:10.1024/0040-5930/a000675 · Cited by 2
Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods
Doecke, J. D., François, C., Fowler, C. J., Stoops, E., Bourgeat, P., Rainey‐Smith, S. R., Li, Q., Masters, C. L., Martins, R. N., Villemagne, V. L., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00812-9 · Cited by 2
Self-citation
Biomarqueurs du liquide cérébrospinal
Leroy, M., Vaudran, L., Deramecourt, V., Pasquier, F., Chen, Y., Schraen‐Maschke, S., & Lebouvier, T. (2021) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2021.03.014 · Cited by 4
Marqueurs biologiques et maladie d’Alzheimer
Quadrio, I., Hay-Lombardie, A., Perret‐Liaudet, A., & Bigot‐Corbel, E. (2021) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(21)00191-x · Cited by 2
Self-citation
Pre-Analytical Processing and Biobanking Protocol for CSF Samples
Teunissen, C. E., & Willemse, E. A. J. (2021) · Neuromethods · doi:10.1007/978-1-0716-1319-1_8 · Cited by 1
Self-citation
Cerebrospinal fluid level of proNGF as potential diagnostic biomarker in patients with frontotemporal dementia
Malerba, F., Florio, R., Arisi, I., Zecca, C., Dell’Abate, M. T., Logroscino, G., & Cattaneo, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1298307 · Cited by 2
A comprehensive Investigation of the associations between cerebral blood flow and cerebrospinal fluid biomarkers across the Alzheimer’s disease continuum
KHOSRAVI, F., Nasiri, H., Alvwandi, F., Kavian, M., Janbazi, M., Gheissari, M. M., Noroozi, M., Atashi, G., Asghari, Z., Majd, N. G., et al. (2025) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2025.109124 · Cited by 1
Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation
Hu, M., Robinson, O., Lill, C. M., Matton, A., Puerta, R., Sánz, P., Boada, M., Ruiz, A., Middleton, L. T., & Initiative, T. A. D. N. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70227 · Cited by 1
Spatial pattern separation deficits in early Alzheimer’s disease are comparable in humans and animal models
Laczó, M., Malenínská, K., Khazaalova, N., Borovská, Š., Vyhnálek, M., HORT, J. F., Stuchlík, A., Svoboda, J., & Laczó, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-36266-y · Cited by 1
Cerebrospinal Fluid Biomarkers of Preclinical Alzheimer’s Disease
Alexopoulos, P., & Sirinian, C. (2018) · Neuromethods · doi:10.1007/978-1-4939-7674-4_6 · Cited by 1
Dementia
Potocnik, F. C. V. (2013) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v19i3.944 · Cited by 1
The Diagnostic Potential of Circulating Autoantibodies to Amyloid-β in Alzheimer’s Disease
Xu, G.-Y., Liu, Y., Zeng, X., Chen, D., Zeng, G., Fan, D., Liu, Y.-H., & Wang, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230252 · Cited by 1
Differentiation of Alzheimer's disease from other neurodegenerative disorders using chemiluminescence immunoassays measuring cerebrospinal fluid biomarkers
Arendt, P., Römpler, K., Brix, B., Borchardt-Lohölter, V., Busse, M., & Busse, S. (2024) · Frontiers in Dementia · doi:10.3389/frdem.2024.1455619 · Cited by 1
Biomarkers of neurodegeneration – not only Alzheimer’s disease and not only cerebrospinal fluid: a guest-editor’s introduction
Lewczuk, P. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0836-5 · Cited by 1
Self-citation
Preanalytical Variables and Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid
Florkowski, C. M. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.240069 · Cited by 1

Authors: Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., Parnetti, L., Perret‐Liaudet, A., Shaw, L. M., Teunissen, C., Wouters, D., & Blennow, K.
Affiliations: Fujirebio (Belgium) (BE)
Kliniken Essen-Mitte (DE)
University of Antwerp (BE)
Department of Neurology and Memory Clinic, Middelheim and Hoge Beuken Hospital Network Antwerp (ZNA) Antwerp Belgium
Universitätsklinikum Erlangen (DE)
Alzheimer's Disease and Other Cognitive Disorders Unit Hospital Clinic i Universitari Barcelona Spain
University of Perugia (IT)
Lyon 1 Université (FR)
University of Pennsylvania (US)
Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
University of Gothenburg (SE)
Corresponding author: Blennow, Kaj
ORCID: Engelborghs, Sebastiaan
Lewczuk, Piotr
Parnetti, Lucilla
Perret‐Liaudet, Armand
Shaw, Leslie M.
Teunissen, Charlotte
Blennow, Kaj
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2011-11-03
Volume: 8
Issue: 1
Pages: 65-73
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2011.07.004
OpenAlex: W2141318707
Cited by: 358
References: 63
Citations by year: 2026: 7 · 2025: 18 · 2024: 33 · 2023: 21 · 2022: 22 · 2021: 29 · 2020: 33 · 2019: 14 · 2018: 19 · 2017: 23 · 2016: 26 · 2015: 42 · 2014: 30 · 2013: 17 · 2012: 23
FWCI: 15.32
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Alzheimer s & Dementia (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Pure Amsterdam UMC (submittedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
Keywords: Alzheimer's disease, cerebrospinal fluid biomarkers
MeSH terms: Alzheimer Disease, Humans, Peptide Fragments, Quality Control, Reproducibility of Results, Biomarkers, Amyloid beta-Peptides, tau Proteins, Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks